下一代细胞疗法:CAR-NK细胞的新兴作用
本文综述了CAR-T细胞疗法在复发或难治性B细胞恶性肿瘤中取得革命性进展后仍存在的自体和异体应用局限,包括实操、物流和毒性问题。鉴于这些顾虑,自然杀伤(NK)细胞因其独特生物学特征和异体应用已确立的安全性,作为CAR工程替代载体受到快速增长的关注。其他免疫效应细胞如恒定自然杀伤T细胞、γδ T细胞和巨噬细胞也受到关注,CRISPR-Cas基因编辑等创新技术有望增强免疫效应细胞清除难治性癌症的天然能力。
要点
- CAR-T细胞疗法存在自体和异体应用局限,包括实操、物流和毒性问题
- NK细胞因独特生物学特征和异体安全性成为CAR工程替代载体
- CRISPR-Cas基因编辑有望增强免疫效应细胞抗肿瘤能力
核心结论
- CAR-NK细胞作为CAR工程替代载体受到快速增长关注,其他免疫效应细胞也可能加入工程化细胞疗法 repertoire。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- CAR-T细胞疗法改变了复发或难治性B细胞恶性肿瘤的治疗范式,但自体和异体应用均存在实操、物流和毒性局限。
- NK细胞具有独特生物学特征和异体应用已确立的安全性,作为CAR工程替代载体兴趣快速增长。
- 恒定自然杀伤T细胞、γδ T细胞和巨噬细胞也作为工程化细胞疗法受到关注。
临床怎么用
- CAR-NK细胞可作为CAR-T细胞疗法局限背景下的替代工程化细胞疗法方向。
- CRISPR-Cas基因编辑技术可用于增强免疫效应细胞清除难治性癌症的天然能力。
局限性
- 摘要未报告综述的检索范围及具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell malignancies. Despite this progress, there are limitations to CAR-T cell therapy in both the autologous and allogeneic settings, including practical, logistical, and toxicity issues. Given these concerns, there is a rapidly growing interest in natural killer cells as alternative vehicles for CAR engineering, given their unique biological features and their established safety profile in the allogeneic setting. Other immune effector cells, such as invariant natural killer T cells, γδ T cells, and macrophages, are attracting interest as well and eventually may be added to the repertoire of engineered cell therapies against cancer. The pace of these developments will undoubtedly benefit from multiple innovative technologies, such as the CRISPR-Cas gene editing system, which offers great potential to enhance the natural ability of immune effector cells to eliminate refractory cancers.
引用
- Basar R, Daher M, Rezvani K, et al. Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv. 2020. PMID: 33232480. doi:10.1182/bloodadvances.2020002547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。